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Abstract 
The loss of zinc transporter 3 (ZnT3)  has been implicated in age-related cognitive decline in 
mice and the protein has been associated with plaques. We investigated the levels of ZnT3 
and PSD95, a marker of the post-synaptic terminal, in people with Parkinson’s disease 
dementia (PDD n=31), dementia with Lewy bodies (DLB n=44), Alzheimer’s disease (AD 
n=16) and controls (n=24), using semi-quantitative western blotting and 
immunohistochemistry in three cortical regions. Standardized cognitive assessments during 
life and semi-quantitative scoring of Aβ, tau and α-synuclein at post-mortem were used to 
investigate the relationship between ZnT3 and PSD95, cognition and pathology. 
 Associations were observed between ZnT3 and PSD95 levels in prefrontal cortex and 
cognitive impairment (p=0.001 and p=0.002 respectively), and between ZnT3 levels in the 
parietal cortex and cognitive impairment (p=0.036). Associations were also seen between 
ZnT3 levels in cingulate cortex and severity of amyloid-β (p=0.003) and tau pathology 
(p=0.011). DLB and PDD were characterized by significant reductions of PSD95 (p<0.05) 
and ZnT3 (p<0.001) in prefrontal cortex compared to controls and AD. PSD95 levels in the 
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parietal cortex were found to be decreased in AD cases compared to controls (p=0.02) and 
PDD (p=0.005).  
This study has identified Zn2+ modulation as a possible novel target for the treatment of 
cognitive impairment in DLB and PDD, and the potential for synaptic proteins to be utilised 
as biomarkers for the differentiation of DLB and PDD from AD. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Whitfield 
4 
 
Introduction 
The Lewy body dementias, incorporating dementia with Lewy bodies (DLB) and Parkinson’s 
disease dementia (PDD) are collectively the second most common neurodegenerative 
dementia (Aarsland, et al., 2008) and are pathologically characterized by α-synuclein, with 
varying amounts of Aβ and tau aggregates in addition to synaptic loss (Dickson, 2002). 
Clinical hallmarks include fluctuating and deteriorating cognition, hallucinations, and 
parkinsonism (McKeith, et al., 2005). 
There is an increasing recognition of the importance of metal ions, in particular zinc, in 
neurodegenerative disorders (Sensi, et al., 2009).  Zn2+ is sequestered into synaptic vesicles 
exclusively by the synapse-specific member of the zinc transporter family, ZnT3, prior to 
release with neurotransmitter as a modulator of neural transmission (Lee, et al., 
2011,Palmiter, et al., 1996,Sensi, et al., 2009); thus ZnT3 is vital for correct synaptic release 
and regulation of Zn2+.  
Ablation of the ZnT3 gene in mice (ZnT3 KO) resulted in age-related memory impairment 
(Adlard, et al., 2010,Sindreu, et al., 2011). It was suggested that ZnT3 mediated synaptic Zn2+ 
homeostasis is important for maintenance of cognition and that loss of ZnT3 and the 
consequent dyshomeostasis of synaptic Zn2+ may adversely affect memory and cognition.  
ZnT3 KO mice also showed decreases in PSD95 (Adlard, et al., 2010). ZnT3 has been found 
associated with plaques in AD (Zhang, et al., 2008). Furthermore, Zn2+ has been shown to 
facilitate aggregation of Aβ (Bush, et al., 1994,Curtain, et al., 2001), tau (Boom, et al., 
2009,Mo, et al., 2009) and α-synuclein (Paik, et al., 1999,Yamin, et al., 2003).  
PSD95 is a post synaptic protein key to the cellular scaffolding and regulation of membrane 
expressed neurotransmitter receptors at the post synaptic terminal. PSD95 is widely 
recognised to have roles in synaptic function including regulation of the localisation of 
membrane proteins and protein trafficking (Han and Kim, 2008). Reductions in PSD95 have 
been observed in AD (Gylys, et al., 2004,Love, et al., 2006), although not consistently 
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(Leuba, et al., 2008), and implicated in learning and memory deficits in mice (Migaud, et al., 
1998,Nyffeler, et al., 2007).    
Despite the possible roles of Zn2+ and synaptic dysfunction in cognitive, behavioural and 
pathological aspects of DLB, PDD and AD, the status of ZnT3 and PSD95 in DLB or PDD 
has not been investigated. Hence, the present study examined the concentration and 
distribution of ZnT3 and PSD95 in post mortem brain tissue retrieved from a large cohort of 
DLB, PDD and AD patients, well characterized clinically and neuropathologically, and 
controls. We aimed to determine what the relationships were between these proteins and 
cognition, and the neuropathological hallmark lesions Aβ, tau and α-synuclein in DLB, PDD 
and AD. It was hypothesised, on the basis of previous literature, that reduced ZnT3 and 
PSD95 would be associated with cognitive impairment in DLB and PDD, specifically in the 
prefrontal cortex as this region is selectively involved in the most prominent cognitive 
changes in these dementias. Furthermore, it was hypothesised that AD cases would have a 
stronger association to changes in the parietal cortex, again due to the prominence of atrophy 
and degenerative changes this region in AD (Guadagna, et al., 2012,Jacobs, et al., 
2012,Jacobs, et al., 2011,Kirvell, et al., 2006). 
2. Methods and Materials 
2.1 Participants, diagnosis and assessment 
Post-mortem brain tissue was obtained from several sources; University Hospital Stavanger 
(Norway), the MRC London Neurodegenerative Diseases Brain Bank, the Thomas Willis 
Oxford Brain Collection and the Newcastle Brain Tissue Resource. The UK brain banks are 
part of the Brains for Dementia Research Network. All participants gave informed consent for 
their tissue to be used in research and the study had ethics approval from the National 
Research Ethics Service (08/H1010/4). Table 1 shows the demographic details of the patients 
and controls. Biochemical and histopathological analysis was undertaken on prefrontal cortex 
(Brodmann area, BA, 9), anterior cingulate gyrus (BA24) and parietal cortex (BA40). BA9 
was selected due to its proposed role in executive function and cognition (Fuster, 2001), 
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decline of which is a cardinal symptom of DLB and PDD, BA24 was selected for the early 
development of pathology encountered in this region in DLB and PDD (Alafuzoff, et al., 
2009) whilst BA40 was selected because of its pathological predominance in AD as opposed 
to DLB and PDD (Alafuzoff, et al., 2008,Guadagna, et al., 2012,Jacobs, et al., 2012,Jacobs, et 
al., 2011,Kirvell, et al., 2006). 
Neuropathological assessment was performed according to standardised neuropathological 
scoring/ grading systems, including Braak staging, Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) scores, Newcastle/ McKeith Criteria for Lewy body disease, 
National Institute on Aging - Alzheimer’s Association (NIA-AA) guidelines and phases of 
amyloid-β (Aβ) deposition (Aβ-phases) (Braak, et al., 2006,McKeith, et al., 2005,Mirra, et al., 
1991,Montine, et al., 2012,Thal, et al., 2002). Controls were neurologically normal, with only 
mild age associated neuropathological changes (e.g., neurofibrillary tangle Braak stage ≤II) 
and no history of neurological or psychiatric disease.  
Cognitive impairment data consisted of the last Mini-Mental State Examination (MMSE) 
scores a maximum of two years prior to death (Folstein, et al., 1975). Although the MMSE is 
not the most sensitive tool for some aspects of DLB and PDD such as executive function 
(McKeith, et al., 2005), its ubiquity made it the only feasible cognitive measure for this study. 
Patients and controls were categorised according to cognitive impairment in the following 
manner; ‘unimpaired cognition’ – for individuals classified by the brain bank(s) as being 
clinical controls, ‘neurodegenerative disease without dementia’ – for individuals with MMSE 
scores of 25 to 30 and no antemortem diagnosis of dementia, ‘mild dementia’ – for 
individuals with MMSE scores from 17 to 24, ‘moderate dementia’ – for individuals with 
MMSE scores of 10 to 16, ‘severe dementia’ for individuals with MMSE scores of 9 or less. 
Final diagnoses for patients are clinico-pathological consensus diagnoses incorporating the 
one-year rule to differentiate DLB and PDD (McKeith, et al., 2005). Earlier reports of at least 
some of the cohorts showed that there was a very good match between clinical and 
pathological diagnosis (Aarsland, et al., 2005). 
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2.2 Immunohistochemistry 
Sections (7µm) of paraffin embedded tissue from BA9 were cut and de-waxed using xylene 
and alcohol. Epitope retrieval consisted of microwaving the sections in citrate buffer 
(Yamashita, 2007). The primary antibodies were anti-ZnT3 (Synaptic Systems, 197-002, 
rabbit polyclonal, 1:200) and anti-PSD95 (Abcam ab18258, rabbit polyclonal, 1:400). Di-
amino-benzidine (DAB, sigma) enhanced with nickel was the visualisation reagent and a 
haematoxylin counter-stain was employed. 
Semi-quantitative assessments of Aβ, tau and α-synuclein pathology were conducted blind to 
clinical diagnosis, by neuropathologists (JA & TH), using a scale of 0 (none), 1 (sparse), 2 
(mild) and 3 (severe/frequent) to score sections from BA9, BA24 and BA40. For detection of 
senile Aβ plaques sections were stained with an anti-Aβ 1E8 or 4G8 antibody (17-24, mouse 
monoclonal, Covance, SIG-39220) at 1:1000. Tau immunohistochemistry (AT8 mouse 
monoclonal antibody, 90206, Innogenetics, at 1:200) and silver impregnation (Gallyas or 
modified Bielschowsky) were used to detect neurofibrillary tangles, neuritic plaques, 
dystrophic neurites and neuropil threads. α-synuclein pathology was detected using NCL-
SYN antibody (KM51, Novocastra Laboratories, Leica Biosystems) at 1:200. Examples of 
these three stains and each category of semi-quantitative score can be seen in figure 5. 
2.3 Preparation of tissue samples for western blotting 
Preparation of tissue for western blotting was as previously described (Kirvell, et al., 2006). 
Briefly, 500mg of frozen tissue was taken from each brain region. Meninges, white matter, 
blood vessels and clots were dissected from the frozen tissue to leave approximately 200mg 
of grey matter which was homogenised in ice cold buffer containing 50mM tris-HCL, 5mM 
EGTA, 10mM EDTA, ‘complete protease inhibitor cocktail tablets’ (Roche, 1 tablet per 50ml 
of buffer), and 2µg/ml pepstatin A dissolved in ethanol:DMSO 2:1 (Sigma). Buffer was used 
at a ratio of 2ml to every 100mg of tissue and homogenisation performed using an IKA Ultra-
Turrax mechanical probe (KIA Werke, Germany) until the liquid appeared homogenous. 
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Protein concentration was established using the Coomassie (Bradford) Protein Assay Kit 
(Thermo Scientific), briefly 10µl of crude homogenate was diluted 1:50 and read in triplicate 
at 595nm using a FlexStation 3 (Molecular Devices). Concentration was calculated using a 
BSA standard curve run at the same time as samples.  
2.4 Western Blotting 
Crude brain homogenate was diluted 4:5 with 5x sample buffer (Genscript MB01015), boiled 
for 5 minutes then stored at -20°C. Samples were loaded at 20µg/ml total protein on 10% 
SDS-polyacrylamide gel for protein separation, transferred to nitrocellulose membrane 
(Hydrobond-C, Amersham) and probed with either anti-PSD-95 (Thermo Scientific, MA1-
045, clone 6G6-1C9, mouse monoclonal IgG2a, 1:7000) or anti-ZnT3 (Synaptic Systems, 
197-002, rabbit polyclonal, 1:5000) and the relevant secondary antibody (IRDye from LI-
COR). Bands were detected using an Odyssey infrared fluorescent scanner, the integral of 
intensity quantified using Odyssey infrared imaging systems application software version 
3.0.16 and expressed as ratios to rat cortex in arbitrary units.                                                                                                                             
2.5 Statistical preparation and analysis 
The normality of the data for each protein was determined using the Shapiro-Wilk test in 
SPSS and normalised where necessary. Regression analysis (enter method in SPSS) of 
normalised data was used to determine the effect of confounding variables (see table 1) on 
protein values; gender significantly predicted ZnT3 values and post-mortem delay (PMD) 
significantly predicted PSD95 values for BA9, ZnT3 values for BA24 were significantly 
predicted by age at death and pH (PSD95 values had no relationship to any confounding 
variables), whilst PMD was a significant predictor of both protein values in BA40. In each 
case, the protein values were subsequently expressed as residuals (unstandardised) created 
from the regression analysis, to eliminate the confounding effect of the demographic variables 
on the protein values. Unstandardised residuals were used in all subsequent analyses. We 
tested for differences in protein levels between groups using one-way ANOVA and 
Bonferroni post-hoc test in SPSS. 
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3. Results 
AD patients were significantly older at death than controls (p=0.007) or patients with DLB 
(p=0.011) or PDD (p=0.003). There were no significant differences in PMD, tissue pH or 
gender between diagnostic groups (table 1). 
3.1 Differences in the levels of ZnT3 and PSD95 between diagnostic groups. 
The image in figure 1 illustrates the typical western blot of ZnT3 and PSD95, showing 
diagnostic and brain regional specific reductions and confirming the presence of a single band 
at approximately 40kDa for ZnT3 and 97kDa for PSD95. 
Significant differences (p<0.05) were detected (using semi-quantitative western blotting) in 
the levels of ZnT3 and PSD95 in the prefrontal cortex (BA9) according to diagnosis (Figure 
1A and 1B). Significant reductions in ZnT3 were seen in both PDD (28%, p=0.0004) and 
DLB (19%, p=0.001) compared to controls (details of statistical analysis are provided in the 
figure caption). There was no significant alteration in the level of ZnT3 protein in patients 
with AD compared to any other group. With respect to PSD95, mean levels were lower in 
both PDD (28% p=0.0001) and DLB (17% p=0.001) compared to controls. Furthermore, 
mean PSD95 levels were lower in PDD compared to AD (19% p=0.012) and DLB (13% 
p=0.036). In support of the changes seen by western blotting, figure 2 illustrates typical 
immuno-labelling of prefrontal cortex sections from each diagnostic group for ZnT3 (figure 
2A-D) and PSD95 (figure 2F-I). In both cases PDD sections have a considerably lower 
staining intensity than control and AD, supporting the evidence from western blotting in 
figure 1A and 1B. The staining intensity for either protein did not differ greatly between 
DLB, AD or controls.  
There was no significant difference in the levels of ZnT3 in the cingulate gyrus (BA24) 
between the diagnostic groups (figure 1C, p>0.05). However, mean PSD95 levels in patients 
with AD were significantly elevated by 23% compared to PDD patients (p=0.027) and by 
25% compared to control (figure 1D p=0.037). 
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There was no significant difference in the levels of ZnT3 in the parietal cortex (BA40) 
between the diagnostic groups (figure 1E, p>0.05). However PSD95 levels were reduced in 
people with AD by 22% compared to controls (p=0.02) and by 24% compared to people with 
PDD (figure 1F p=0.005). 
3.2 Reductions in ZnT3 and PSD95 were associated with cognitive impairment. 
The reduced levels of ZnT3 and PSD95 detected in BA9 were found to be associated with 
cognitive impairment (figure 3A and 3B; R2=0.297, beta= -0.339, df 2,77, t= -3.325, p=0.001 
and beta= -0.325, df 2,77, t= -3.194, p=0.002 respectively), this analysis included all control, 
DLB and PDD subjects. In addition, in pairwise comparisons, patients with mild dementia 
had mean ZnT3 and PSD95 levels that were significantly lower than individuals with 
unimpaired cognition (ZnT3, 24% p=0.013, PSD95 19% p=0.028) and levels of both proteins 
were significantly lower in people with moderate dementia (both 24%, ZnT3 p=0.001, PSD95 
p=0.0001) and with severe dementia (both 24%, ZnT3 p=0.005, PSD95 p=0.002) compared 
to controls. Upon inclusion of AD patients in the analysis, ZnT3 and PSD95 levels in BA9 
were still associated with cognitive impairment but the association was weaker (ANOVA, 
F=14.282, p<0.001 R2=0.243, beta= -0.320, df 2,89, t= -3.271, p=0.002 and beta= -0.283, df 
2,89, t= -2.895, p=0.005 respectively). 
Reduced levels of ZnT3 in BA40 were also associated with cognitive impairment (figure 3C, 
ANOVA, F=4.540, R2= 0.48, beta= -0.218, df 1,91, t= -2.131, p=0.036) according to 
regression analysis of all controls and dementia patients, but were not significantly different 
between people with different severities of cognitive impairment (one-way ANOVA p>0.05). 
When AD patients were excluded there was no significant relationship between cognition and 
either protein in BA40 (p>0.05). No associations were found between ZnT3 or PSD95 levels 
and cognition in BA24 (p>0.05, data not shown).  
3.3 Relationships between synaptic proteins and neuropathological scores 
In BA24, ZnT3 levels were inversely associated with the semi-quantitative scores for both Aβ 
pathology (figure 4A, ANOVA, F=9.292, R2=0.91, beta=-0.301, df 1,93, t= -3.048, p=0.003) 
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and tau pathology (figure 4B, ANOVA, F=6.687, R2= 0.065, beta=-0.255, df 1,96, t= -2.586, 
p=0.011) according to regression analysis of all dementia patients and controls. However 
there was no association between ZnT3 and these scores for other brain regions (p>0.05, data 
not shown).  Furthermore, there was no association between ZnT3 levels and α-synuclein 
pathology in any of the brain regions examined (p>0.05, data not shown). PSD95 did not 
relate to any neuropathological scores in any brain region (p>0.05, data not shown). 
4. Discussion 
The principal observation of this study was an association between reduced ZnT3 and PSD95 
in the prefrontal cortex and cognitive impairment in DLB and PDD cases, which is consistent 
with the selective involvement of this region in Lewy body dementias. Other important 
findings were: decreased levels of ZnT3 and PSD95 in the prefrontal cortex of PDD and DLB 
cases compared to controls; increased PSD95 in the cingulate gyrus of AD cases compared to 
controls and PDD; and decreased PSD95 levels in the parietal cortex of AD cases compared 
to controls and PDD. Additionally, levels of ZnT3 inversely correlated with both Aβ and tau 
pathology in the cingulate gyrus (BA24) but not in the other regions studied. 
Significant strengths of this study include the large number of patients with DLB and PDD 
and the undertaking of brain region specific pathology scores. Additionally, the semi-
quantitative changes observed by western blotting were supported by a small selection of 
cases examined immunohistochemically, although it is recognised that the latter technique 
was not quantified. One limitation inherent in post-mortem studies is the differences in 
demographics and epiphenomena between groups, this has been addressed statistically 
through the creation of residuals. Another limitation is the observational nature of the results 
reported, although this is mitigated by the previously reported mechanistic animal studies on 
ZnT3 implicating this protein in cognition (Adlard, et al., 2010). 
The observed reductions in ZnT3 and PSD95 in prefrontal cortex of DLB and PDD patients 
are consistent with consensus that these dementias are characterized by greater frontal 
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degeneration in comparison to AD, whilst the greater reduction in these proteins in BA40 in 
AD is consistent with more extensive parietal degeneration in AD (Burton, et al., 2012).  
 
Increases in PSD95 have been previously reported in AD cases, although this was in frontal 
cortex (BA9), and was attributed to compensatory mechanisms at the post-synaptic terminal 
(Leuba, et al., 2008). 
It has been previously reported that ablation of ZnT3 by gene deletion in mice is associated 
with age-related cognitive deficits (Adlard, et al., 2010). One possible explanation for this is 
that Zn2+ is co-released with glutamate, acting as a long term modulator of synaptic plasticity, 
and thus is important for cognition (Sensi, et al., 2009). Our findings suggest this association 
between a loss of ZnT3 and cognitive deficits extends to humans and is more pronounced in 
DLB and PDD than AD. Controls, DLB and PDD patients were included in the analysis to 
achieve a gradation of all stages of cognitive impairment. This association is probably related 
to frontal synaptic dysfunction, and as reduced PSD95 was also predictive of cognitive 
deficits. Interestingly,  decreased Zn2+ concentration at the post-synaptic density has been 
shown in vitro to cause reductions in PSD95 (Grabrucker, et al., 2011a).  
Furthermore, Zn2+ has been implicated in Aβ and tau aggregation in vitro (Boom, et al., 
2009,Bush, et al., 1994,Curtain, et al., 2001,Mo, et al., 2009) In this context our findings of an 
association between reduced ZnT3 in BA24 and increases in both Aβ and tau pathologies are 
consistent with the in vitro studies and suggest a loss of regulation of synaptic Zn2+ to have a 
contributory role in the production of pathology within this region.  BA24 is noted for the 
early development of pathology in DLB and PDD (Alafuzoff, et al., 2009). Indeed, the 
present findings may support Adlard and colleagues who proposed a ‘dual hit’ model in 
which dyshomeostasis of synaptic Zn2+ denies zinc its role in cognition, as less Zn2+ is co-
released with neurotransmitter, whilst allowing the build-up of Zn2+ destined to be packaged 
into vesicles to instead promote protein aggregation (Adlard, et al., 2010). A similar concept 
was proposed by Grabucker and colleagues in response to their evidence of Aβ sequestration 
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of Zn2+ depleting the post-synaptic density (Grabrucker, et al., 2011b). The present evidence 
of associations between AD pathology and loss of Zn2+ regulation suggests these theories are 
relevant to the disease process in man.  
If indeed some of the pathology is associated directly with zinc dyshomeostasis, there is no 
evidence from the present study that this is linked to cognitive impairment since the 
correlation between reductions in ZnT3 and cognitive impairment and between ZnT3 and AD 
pathology occurred in different brain regions. However, it should be noted that BA9 and 
BA24 are highly interconnected (Li, et al., 2013). Further mechanistic investigation, such as 
in vitro or animal studies, is warranted to elucidate the exact nature of the relationship 
between ZnT3, pathology and cognition. In particular it would be interesting to examine 
whether soluble oligomers of the key pathological proteins provide a better correlate to zinc 
dyshomeostasis in the other brain regions given the lack of relationship to pathological 
deposition outside of BA24. 
To our knowledge this is the first study to connect ZnT3 to cognition in man despite 
investigations of ZnT3 levels in AD (although not DLB and PDD). Adlard and colleagues and 
Bjorklund and colleagues have reported reduced ZnT3 levels in AD patients. Whilst we did 
not find a significant reduction in ZnT3 levels in AD patients, ZnT3 levels were reduced 
compared to controls in BA9, BA24 and BA40 (by 16%, 11% and 18% respectively). This is 
despite a higher number of AD patients in the present study than that reported by Adlard and 
colleagues (Adlard, et al., 2010) and only 5 fewer AD patients than Bjorklund and colleagues 
(Bjorklund, et al., 2012) and serves to highlight the variability inherent in human post-mortem 
protein studies. 
Our findings of reduced PSD95 and ZnT3 in prefrontal cortex of DLB and PDD but not AD 
or control suggest this could be explored as a biomarker for differentiating DLB and PDD 
from other aged individuals. There have been no reports concerning ZnT3 or PSD95 in CSF 
or blood; however some synaptic proteins can be detected in CSF, whilst others such as 
synaptophysin are not detectable (Davidsson, et al., 1999,Schlaf, et al., 1998). 
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Importantly, the modulation of Zn2+ by a compound (PBT2) is under investigation as a 
potential treatment for AD.  PBT2 has been shown to improve cognition in AD patients 
possibly through reducing zinc mediated Aβ aggregation and increasing intracellular 
bioavailability of Zn2+, this latter action may offset the loss of ZnT3 (Adlard, et al., 
2008,Crouch, et al., 2011,Lannfelt, et al., 2008). Our findings suggest a similar approach 
might be appropriate for DLB and PDD because of the possible contribution of Zn2+ 
dyshomeostasis (as a consequence of reduced ZnT3) to cognitive impairment in these 
dementias. Furthermore, approximately 90% of the DLB cases in this study had levels of AD 
pathology sufficient to meet the CERAD criteria for probable AD so it is conceivable that this 
concurrent pathology may be more susceptible to zinc modulation. 
It is clear, both from our findings with PSD95 and from the general literature, that there are 
very likely multiple synaptic correlates of cognitive impairment, we have identified two. 
Thus, in conclusion, we present evidence that a loss of regulation of synaptic Zn2+ may have a 
role in cognitive impairment in the Lewy body dementias and raise the possibility of 
modulating Zn2+ as a disease-modifying approach in DLB and PDD. 
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Tables and Figures 
 
Diagnosis Gender (M/F) 
% 
Age at 
death 
PMD  pH MMSE Braak 
stage 
Control 
(25) 
60/40 79.8  ± 1.5 39.1  ± 
4.6 
6.47  ± 
0.05 
n/a 1 (0-2) 
PDD (34) 53/47 79.9  ± 1.0 33.5  ± 
2.7 
6.44  ± 
0.06 
13 (0-27) 2 (0-6) 
DLB (45) 58/42 81.3  ± 1.0 42.4  ± 
4.2 
6.34  ± 
0.06 
13 (0-30) 4 (1-6) 
AD (16) 31/69 88.0  ± 2.0 34.9  ± 
6.0 
6.30  ± 
0.08 
10.5 (0-
19) 
4 (4-6) 
 
Table 1; Demographic characteristics of the subjects used in this study according to 
clinical diagnosis, (± SEM); age at death, PMD and pH are mean values, MMSE is 
the median score prior to death and Braak stage is median, both with range in 
brackets. One-way ANOVA and bonferroni post-hoc test revealed AD patients to 
have a significantly higher age at death than all other diagnostic groups (ANOVA; 
F(3,106)5.015, p=0.003, post-hoc; control p=0.007, PDD p=0.003 and DLB p=0.011). 
There was no significant difference between diagnostic groups for any of the other 
variables except cognition and pathology, for which subsequent analysis is shown in 
figures 3 and 4. PMD is post-mortem delay. 
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Figure 1: ZnT3 and PSD95 levels, from semi-quantitative western blotting in BA9, 
BA24 and BA40, according to diagnosis. 
BA9 
Statistical analysis was performed using One-way ANOVA and Bonferroni post-hoc 
test. In BA9: ZnT3 values (graph A) from controls were significantly higher than 
PDD (p=0.0004) and DLB (p=0.001), whilst PSD95 values (graph B) from controls 
were significantly higher than the PDD (p=0.0001) and DLB (p=0.001) groups. 
PSD95 values from the PDD were significantly lower than AD (p=0.012) and DLB 
(p=0.036). The ANOVA values were as follows; PSD95; F=(3,108)12.809,  
p=0.0003, ZnT3; F=(3,111)9.409, p=0.0001.  
BA24 
In BA24 there was no significant difference in ZnT3 levels between diagnostic groups 
(graph C, p>0.05) but PSD95 levels (graph D) were significantly higher in AD 
patients compared to controls (p=0.037) and PDD patients (p=0.027). ANOVA 
values: F=(3,100)3.745, p=0.013. 
BA40 
In BA40 there was no significant difference in ZnT3 levels between diagnostic groups 
(graph E). PSD95 values (graph F) in AD were significantly lower than control 
(p=0.02) and PDD (p=0.005). The ANOVA values were F=(3,86)5.04, p=0.003. The 
bars represent the mean values with SEM and n values in brackets under bars. For all 
figures *=p<0.05, **=p<0.01 and ***=p<0.001. 
The image (G) shows an example of the diagnosis specific reductions detected by 
western blot for PSD95 and ZnT3. PSD95 was visible on the red channel, ZnT3 on 
the green channel. The samples run on this gel were (from left to right); rat cortex, 
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BA9 AD (x3), BA24 AD (x2), BA40 AD (x5), mwm, rat cortex, BA40 AD (x1), 
BA40 PDD (x9) and rat cortex. 
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Figure 2: Examples of ZnT3 and PSD95 immuno-labelling in prefrontal cortex 
according to diagnosis 
Coronal sections of BA9 were labelled for ZnT3 (images A-F, A=control, B=AD, 
C=PDD, D=DLB, E=no primary antibody, F=control) or PSD95 (images G-K, G = 
control, H = DLB, I = PDD, J = AD, K = no primary antibody). It can be seen that 
PDD sections had very low levels of neuropil staining, almost comparable to no 
primary antibody, and that DLB cases had slightly lower staining than control and 
AD. Scale bars = 10 µm and all images are 40X except image F which is 63X. 
 
Figure 3: ZnT3 and PSD95 protein levels in BA9 and ZnT3 protein levels in BA40 
predicted cognitive impairment. 
BA9 
Regression analysis showed ZnT3 and PSD95 levels in BA9 of control, DLB and 
PDD cases to be significant predictors of the cognitive impairment category 
(R2=0.297, beta= -0.339, df 2,77, t= -3.325, p=0.001 and beta= -0.325, df 2,77, t= -
3.194, p=0.002 respectively, ZnT3 graph A, PSD95 graph B). The ANOVA for the 
model was significant (p=0.0001). The cognitive impairment groups were; ‘controls’ 
(assigned a value of 1 and including all designated controls, ZnT3 n=24, PSD95 
n=23), ‘neurodegenerative disease without dementia’ (cases assigned a value of 2 and 
based on a MMSE score of 25 to 30, ZnT3 n=7, PSD95 n=8), ‘mild dementia’ 
(assigned a value of 3 and based upon a MMSE score of 17 to 24, ZnT3 n=12, PSD95 
n=12), ‘moderate dementia’ (assigned a value of 4 and based upon a MMSE score of 
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10 to 16, ZnT3 n=23, PSD95 n=22) and ‘severe dementia’ (assigned a value of 5 and 
based upon a MMSE score of 9 or less, ZnT3 n=19, PSD95 n=18). The difference in 
mean PSD95 and ZnT3 levels between cognitive impairment groups was analysed by 
one-way ANOVA and the Bonferroni post-hoc test, which revealed ZnT3 levels to be 
significantly higher in controls compared to people with severe dementia (p=0.005), 
moderate dementia (p=0.001) and mild dementia (p=0.013). PSD95 levels were 
calculated to be significantly higher in controls than in individuals with mild dementia 
(p=0.028), moderate dementia (p=0.0001) and severe dementia (p=0.002). The 
ANOVA values were F(4.78)=6.819, p=0.00009 for PSD95 and F(4.80)=5.827, 
p=0.0004 for ZnT3.  
BA40 
Additionally, regression analysis showed ZnT3 levels in BA40 to be a significant 
predictor of the cognitive impairment category (R2=0.048, beta= -0.218, df 1,91, t= -
2.131, p=0.036 graph C). The ANOVA for the model was significant (F=4.540, 
p=0.036). The difference in mean ZnT3 levels between cognitive impairment groups 
was not found to be significant according to a Kruskal Wallis test (p=0.093). 
‘Unimpaired cognition’ (1) n=22, ‘neurodegenerative disease without dementia’ (2) 
n=8, ‘mild dementia’ (3) n=14, ‘moderate dementia’ (4) n=24 and ‘severe dementia’ 
(5) n=25. 
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Figure 4: ZnT3 protein levels, from semi-quantitative western blotting, predicted the 
plaque and tangle scores in BA24. 
Regression analysis showed ZnT3 values in BA24 to be a significant predictor of the 
semi-quantitative plaque score (R2=0.091, beta= -0.301, df 1,93, t= -3.048, p=0.003 
graph A). The ANOVA for the model was significant (F=9.292, p=0.003). Plaque 
score; none (1) n=40, sparse (2) n=27, moderate (3) n=16 and severe (3) n=12. The 
difference in mean ZnT3 levels between plaque score groups was analysed by one-
way ANOVA and the Bonferroni post-hoc test, which revealed ZnT3 levels to be 
significantly lower in subjects with a severe plaque score compared to subjects with a 
plaque score of absent (p=0.029); for the ANOVA F(3.91)=3.331, p=0.023. 
Additionally, ZnT3 was found to be a significant predictor of the semi-quantitative 
tangle score in BA24 (R2=0.065, beta= -0.255, df 1,96, t= -2.586, p=0.011 graph B). 
The ANOVA for the model was significant (F=6.687, p=0.011). Tangle score; none 
(1) n=46, sparse (2) n=31, moderate (3) n=12 and severe (3) n=9. The difference in 
mean ZnT3 levels between tangle score groups was analysed by one-way ANOVA 
and the Bonferroni post-hoc test, which revealed no significant difference between 
tangle score groups. 
Figure 5.1; Images of Aβ staining representative of the four categories of semi-
quantitative score. 
For each set of images, the whole section was viewed to determine the semi-
quantitative score, representations of each score category are shown; and in each set 
image A is from a case given a score of absent/0, image B is from a case given a score 
of sparse/1, image C is from a case given a score of moderate/2 and image D is from a 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Whitfield 
27 
 
case given a score of severe/3. The horizontal bar is 50µm. See the methods section 
for further details. 
Figure 5.2; Images of tau staining representative of the four categories of semi-
quantitative score. 
 
Figure 5.3; Images of α-synuclein staining representative of the four categories of 
semi-quantitative score. 
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